Proactive Approaches to Communicating with FDA

Formal Advisory Request Process

Request for meeting

Submit a complaint about competitor

Voluntary Compliance

Advisory Request Process

Why

- Area of uncertainty for company
- Mitigate risk for potential violation

When

- Prior to promotion in marketplace
- Promotion with great public exposure
- New product campaign
- Interpreting new FDA Guidance

How

- Cover letter, proposed promotion, references
- Note to reviewer, optional
- Separate submission path from 2253; eCTD or paper
- Launch vs Non-Launch

Strategic Considerations

Go-to-Launch Promotion vs Seek Advice

Aspect to Mitigate

Best Tactic
Type

Length of Time for Response

Option to withdrawal

Potential Consequences

Receive Written Correspondence from FDA

Potential Impact to Active Promotion for Requested Product and Other Products

Receive Change of Opinion with 90 days to Update Active Promotion [21 CFR 202.1 (j)(4)]

Advice Difficult to Interpret

Request a Meeting

Potential Purposes

- Input on Study Design for Future Use in Promotion
- Interpret new FDA Guidance
- Innovative Promotional Approach

Response

- Rarely Granted Prior to Written Correspondence or Prior to Product Approval
- Typically Granted After Enforcement Action
- If Granted Teleconference Format with Pre-Reads and Specific Questions

Complaint about Competitor Activity

Alert OPDP by providing examples of potential violation

Identify areas of concern

Notify OPDP via

call first

Submit letter via postal mail

Acknowledge receipt and conduct assessment

May request
update on status
after complete
or action taken

Voluntary Compliance Communication

Inform FDA when company identifies potential violation of its promotional material already introduced into marketplace

Content

- Description of promotion
- Concern
- Public exposure
- Company actions to rectify
- Actions taken to prevent reoccurrence

Strategic Consideration

- Demonstrates company active surveillance program to self-identify and correct
- Shows understanding of laws/regulations and intention to disseminate compliant communications

Potential Consequences

- Regardless of proactive notification, FDA could still enforce
- Company could be alerting FDA to issue that may have been otherwise missed